Your session is about to expire
← Back to Search
Exercise + Liraglutide for Type 2 Diabetes (ZQL007 Trial)
ZQL007 Trial Summary
This trial is testing whether exercise, liraglutide, or a combination of the two can improve cardiac and muscle function in people with type 2 diabetes.
ZQL007 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowZQL007 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 4 trial • 100 Patients • NCT02014740ZQL007 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am between 21 and 60 years old.My family has a history of thyroid cancer or genetic syndromes affecting multiple glands.I have been on the same dose of my medications for over 4 months.Your A1C level is lower than 8.5%.My BMI is over 35.I have a history of heart, lung, liver, or kidney disease.I have never taken GLP-1RA or DPP4I medications.I am currently taking insulin.You have smoked in the last 6 months.Your blood pressure is higher than 160/90.You are allergic to perflutren, which is in Definity.I have a history of heart attack, stroke, or poor blood circulation.I have been on a stable dose of diabetes medication for over 4 months.My doctor will check for abnormal heart or lung connections during my exam.
- Group 1: Exercise + Liraglutide
- Group 2: Liraglutide alone
- Group 3: Exercise Alone
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants is the clinical trial currently recruiting?
"Affirmative, the clinicaltrials.gov website attests that this examination is currently recruiting participants. This investigation, which was initially published on February 28th 2019, necessitates 60 patients from a solitary medical centre for completion."
To what extent could Liraglutide have deleterious effects on an individual's wellbeing?
"Liraglutide has already been approved for medical use, which led our team at Power to rate its safety a 3 on the scale of 1-3."
To what maladies has Liraglutide been linked as a potential curative agent?
"Liraglutide is often prescribed as part of a tailored exercise program. Additionally, it can be employed to manage inadequacies that arise from monotherapy, reduce cardiovascular risk and even treat specific cases of cardiovascular disease (CVD)."
Is eligibility for this clinical experiment restricted to individuals below a certain age?
"The age of eligibility for this trial is set between 21 and 60 years old."
What type of participant is the ideal candidate for this trial?
"This medical trial is recruiting 60 individuals between 21 and 60 who have type 2 diabetes. The applicability criteria include: being within the age range, having an A1C of 8.5% or lower, never using GLP-1RA such as exenatide or liraglutide, staying on a stead dose of oral hypoglycemic agents for over 4 monthsm and maintaining similar parameters with other medications for at least that period too."
Are new participants being welcomed into this experimental program?
"Per the clinicaltrials.gov website, this clinical trial is currently in need of participants. It was initially listed on February 28th 2019 and last modified March 7th 2022."
Share this study with friends
Copy Link
Messenger